Superior Planning, LLC’s Trevi Therapeutics TRVI Stock Holding History

Superior Planning, LLC’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$244	Buy	+17	New	+$292	﹤0.01%	2016

Other funds holding TRVI

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Superior Planning, LLC's TRVI Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Trevi Therapeutics (TRVI) in Q3 2026: 17 shares worth $244. The stake represents ﹤0.01% of the portfolio and ranks #2016 among its holdings.

110 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

Superior Planning, LLC held 17 shares of Trevi Therapeutics worth $244 as of Q3 2026.
Trevi Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Trevi Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2016 holding.
110 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.